Melt Pharmaceuticalsincis A Clinical Stage Pharmaceutical Company Dedicated To Enhancing Procedural Sedation With Non Invasiveopioid Free Solutionsthe Company Specializes In Developing Sublingual Tablet Formulations Aimed At Improving Patient Experiences During Ophthalmic Surgeriesparticularly Cataract Procedurestheir Focus Is On Needle Free Sedation And Opioid Sparing Alternativeswhich Help Reduce Complications Associated With Traditional Iv Administration The Flagship Productmelt 300Is A Fast Dissolving Sublingual Tablet That Combines 3Mg Midazolam And 50Mg Ketamineit Features A Rapid 3 Second Dissolution Time And Has Shown Positive Results In Phase 3 Clinical Trialsmelt Pharmaceuticals Utilizes Proprietary Sublingual Delivery Systems To Enhance Pharmacokineticsminimize Systemic Side Effectsand Improve Patient Compliancethe Company Is Advancing Its Clinical Programs With Recent Funding And Is Aligned With Fda Regulatory Pathways To Support Its Innovative Approach To Sedation In Medical Procedures
No conferences found for this company.
| Company Name | Melt Pharmaceuticals |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
